5,100
Participants
Start Date
March 31, 2026
Primary Completion Date
June 30, 2027
Study Completion Date
June 30, 2028
MoxDA - Moxidectin + Diethylcarbamzine (DEC) + Albendazole
"Mass drug administration with moxidectin co-administered with DEC and albendazole (MoxDA).~Participants who are ineligible to receive moxidectin will be offered modified treatment options:~1. Children aged ≥ 2 years but \< 4 years - DEC, albendazole, and permethrin 5% cream~2. Participants who have a severe illness, a known or suspected allergy to ivermectin, moxidectin, DEC or albendazole, are pregnant or breastfeeding a baby up to 7 days of age, or are under 2 years of age - permethrin 5% cream (unless allergic)"
IDA - Ivermectin + DEC + albendazole
"Mass drug administration with ivermectin co-administered with DEC and albendazole (IDA).~Participants who are ineligible to receive moxidectin will be offered modified treatment options:~1. Children aged \< 2 years or weight \< 15 kg - DEC, albendazole, and permethrin 5% cream~2. Participants who have a severe illness, a known or suspected allergy to ivermectin, moxidectin, DEC or albendazole, are pregnant or breastfeeding a baby up to 7 days of age, or are under 2 years of age - permethrin 5% cream (unless allergic)"
Ministry of Health and Medical Services Fiji, Suva
Collaborators (2)
Murdoch Childrens Research Institute
OTHER
Kirby Institute
OTHER_GOV
Medicines Development for Global Health
OTHER